Close
ACHEMA MIDDLE EAST 2026

Three Viruses That Pharma Sector Needs To Gear Up Against

More than half of the known infectious diseases are getting worse due to climate change. Monkeypox is expanding, and recently, news of an outbreak...

New Zealand Advances Alzheimers Drug Development Process

Researchers from the University of Otago in New Zealand have taken advantage of a brain protein that has a strong chance of delaying or...

Pharma Criticises Drug Pricing Bill As Patient Groups Cheer

The pharmaceutical lobbying group's aura of invincibility has faded. The U.S. Senate recently passed a new bill, leaving the pharmaceutical sector licking its wounds...

How The Pharmaceutical Sector Is Striving To Cut Emissions?

As competing businesses rushed to deliver the first COVID-19 vaccine starting in early 2020, the pharmaceutical sector has been in the press more than...

Pharmacopoeias To Promote Vaccine Development And Supply

The mRNAVAC Working Party was established by the European Pharmacopoeia Commission to start developing standards of quality to support the developing area of messenger...

Why Children Are Better Protected Against COVID-19 & More

There were a lot of mysteries surrounding COVID-19, some of which have been answered, but many more have not. Since the start of the...

With $6.26bn In Q1, The Indian Pharma Exports Grew By 8%

Indian pharmaceutical exports increased by 8% in the first quarter of the current fiscal year to $6.26 billion, with officials anticipating a 10% increase...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...